Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCzech Lymphoma Study Group

About this trial

The Czech National Lymphoma Registry (NiHiL) was founded to monitor epidemiologic data and improve the diagnostic evaluation and quality of treatment of patients with non-Hodgkin´s lymphoma (NHL).

The patients are registered into the registry in anonymized form. For each patient are available: registration form, diagnostic form, treatment form, follow- up form, and other malignancy form.

Data quality in the NiHiL has been checked by audits. The data is analyzed according to NHL subtypes with endpoints: lymphoma distribution, epidemiological data, prognostic characteristic, treatment characteristics, response rate, relapse rate, mortality, PFS, OS, DFS, Lymphoma specific survival, longterm toxicity.

Eligibility criteria

Qualifiers

lymphoma diagnosis

treated in the Czech Republic

signed informed consent

Disqualifiers

unsigned informed consent

age <18 y

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

20,000 Participants
are grouped into 8 trial groups

8

Trial groups

See each trial group below.

Locations

1
Charles University General Hospital128 08, Prague Czechia

Sponsors and collaborators

Czech Lymphoma Study Group

Lead sponsor